Income from Transition Services Agreement	9 Months Ended
Sep. 30, 2025
Collaboration Agreements [Abstract]
Income from Transition Services Agreement	6. Income from Transition Services Agreement In August 2025, we entered into a transition services agreement (“TSA”) with an unrelated party (“TSA Party”) to provide certain services unrelated to our principal operations, which represent the only performance obligation under this arrangement. During the three and nine months ended September 30, 2025, the Company recorded $1.0 million in connection with the TSA, which is presented separately as other income from transition services agreements in the unaudited condensed consolidated statements of operations. The corresponding amounts for the three and nine months ended September 30, 2024 represent income from a different transition services agreement with BridgeBio Pharma (Note 13).

Income from Transition Services Agreement

9 Months Ended

Sep. 30, 2025

Income from Transition Services Agreement

6. Income from Transition Services Agreement

In August 2025, we entered into a transition services agreement (“TSA”) with an unrelated party (“TSA Party”) to provide certain services unrelated to our principal operations, which represent the only performance obligation under this arrangement. During the three and nine months ended September 30, 2025, the Company recorded $1.0 million in connection with the TSA, which is presented separately as other income from transition services agreements in the unaudited condensed consolidated statements of operations. The corresponding amounts for the three and nine months ended September 30, 2024 represent income from a different transition services agreement with BridgeBio Pharma (Note 13).

BridgeBio Oncology Therapeutics, Inc. 10-Q